EPA, DHA, and endometrial cancer type I

 
 
 

Endometrial cancer (endometrium is the inner lining of the womb) is the most common gynecologic cancer and the fourth most common for women worldwide. A PTEN gene mutation is present in approximately 40-80% of endometrial cancer cases, but its mutations have been also found in other types of cancer: prostate and colorectal cancers, some brain tumors and melanoma (skin cancer). This gene provides instructions to our body for making an enzyme that is found in almost all tissues. And this enzyme helps regulate cell division by keeping cells from growing and dividing too rapidly or in an uncontrolled way, and also helps control cell migration, the adhesion of cells to surrounding tissues, and the formation of new blood vessels. All of these functions help prevent uncontrolled cell growth that can lead to the formation of tumors. There lies its importance.

Many studies have revealed a protective effect of long chain omega-3 fatty acids on the development of cancer and its intake has been shown to reduce various cancers (such as colon, breast, and prostate cancers) and alleviate their complications. Specifically, long-term high intake of diets or supplements enriched in EPA and DHA is also associated with lower risk of endometrial cancer.

Now, we know a little bit more: EPA and DHA can powerfully suppress the beginning and progression of endometrial cancer type I (with a mutation in PTEN gene). This offers a new prevention and treatment strategy of this disease to women. Welcome it is!

 

Bibliography: